The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer

European Urology

Volumn 43, Issue 6, 2003, Pages 609-614

  Martínez, Manuel ^a   Navarro, Silvia ^a   Medina, Pilar ^a   Villavicencio, Humberto ^b   Rioja, Luis ^c   Solsona, Eduardo ^d   Estellés, Amparo ^a   Aznar, Justo ^a   Jiménez Cruz, J Fernando ^a   España, Francisco ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Complexed prostate specific antigen; Plasma; Prostate cancer staging

Indexed keywords

CHYMOTRYPSIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC;

EID: 0038700606     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00149-0     Document Type: Article

References (30)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined cancer is increased through prostate-specific antigen based screening. JAMA 1993;270:948-54.
2. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of nonpalpable (Tlc) prostate cancer. JAMA 1994;271:368-74.
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445-51.
4. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
5. 2-macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Internat 1995;37:917-23.
6. 1-antichymotrypsin is the mayor form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
7. 1-antichymotrypsin complexes in serum. Eur J Clin Chem Clin Biochem 1991;29:787-94.
8. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
9. 1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 1996;30:512-8.
10. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995;46:187-94.
11. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
12. España F, Martínez M, Royo M, Vera CD, Estellés A, Aznar J, et al. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia. Eur Urol 1997;32:268-72.
13. 1-antitrypsin in the early detection of prostate cancer. Eur Urol 2000;38:85-90.
14. 1-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 μg/l. Clin Chem 2002;48:1251-6.
15. Pannek J, Subong EN, Jones KA, Marschake PL, Epstein JI, Chan DW, et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 1996;48:51-4.
16. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 1996;155:415A.
17. Bangma CH, Kranse R, Blijenberg BG, Schroeder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997;157:544-547.
18. 1-antichymotrypsin in blood samples. Urology 1996;48:81-7.
19. España F, Royo M, Martínez M, Enguídanos MJ, Vera CD, Estellés A, et al. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol 1998;160:2081-8.
20. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-23.
21. Schoojans F, Zalata A, Depuydt CE, Comhaire FH. MedCalc: a new computer program for medical statistics. Comput Meth Progr Biomed 1995;48:257-62.
22. Prestigiacomo AF, Lilja H, Petterson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996;156:350-4.
23. Filella X, Alcover J, Molina R, Rodríguez A, Carretero P, Ballesta AM. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. Eur J Cancer 1997;33:1226-9.
24. Ravery V, Boccongibod L. Free/total prostate-specific antigen ratio. Hope and controversies. Eur Urol 1997;31:385-8.
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
26. Feneley MR, Partin AW. Indicators of pathologic stage of prostate cancer and their use in clinical practice. Urol Clin North Am 2001;28:443-57.
27. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
28. Graefen M, Hammerer P, Henke P, Hilz H, Huland E, Huland H. Percentage of free PSA does not correlate with pathological outcome. J Urol 1996;155:370A.
29. Morote J, Raventos CX, Lorente JA, Encabo G, de Torres I, López MA, et al. Análisis del porcentaje de PSA lbre en la predicción del fallo quirúrgico potencial en pacientes sometidos a prostatectomía radical. Actas Urol Esp 1999;23:127-34.
30. Katz AE, de Vries GM, Benson MC, Buttyan RE, O'Toole K, Rubin MA, et al. The role of the reverse transcriptase polymerase chain reaction assay for prostate specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am 1996;23:541-9.